Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. 

Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA. 

Biotechnology

Health Care

Life Sciences

Therapeutics

Emmecell

Emmecell's headquarters in Menlo Park, United States

Description

People (6)

Noelia Kunzevitzky

Cyril Allouche

Onkar Sawant

Christy Fleming

Seong Son

Rain Wen

Jobs